Video Series

The OncoloGIST

April 20th 2026

Investigating New Therapies for High-Risk Therapy-Related MDS

February 5th 2026

2026 Cancer Statistics Report

January 15th 2026

Integrating Behavioral Health into Oncology: A Collaborative Approach

January 7th 2026

2025 Oncology Icons: Dr Benjamin George

December 19th 2025

Dr Rodriguez Otero on LINKER-SMM1

September 23rd 2025

Dr Mukherjee on Treatment Disparities in MDS

August 29th 2025

Dr Jazaeri on a New Approach to Undetectable Ovarian Cancer

August 22nd 2025

Dr Dhakal on Sequential Targeting in Myeloma

August 20th 2025

Dr Garcia-Manero on the COMMANDS Trial

August 13th 2025

Comparing ARPIs in Prostate Cancer Treatment

August 11th 2025

Targeted Therapies in Biliary Tract Cancer

August 6th 2025

Exploring Daratumumab in Smoldering Multiple Myeloma

August 4th 2025

Fertility Preservation for Patients With Cancer

July 28th 2025

Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd

July 28th 2025

Chief Insights in Oncology

July 24th 2025

Incorporating Immunotherapy Into the CRC Treatment Landscape

July 23rd 2025

Dr Aizer on Personalizing Radiation for Brain Mets

July 14th 2025

Dr Aldoss on the PhALLCON Study of Ponatinib in Ph+ ALL

July 11th 2025

Personalizing Therapy and Assessing Risk in Hodgkin Lymphoma

July 11th 2025

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients

Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer

NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC

What Stood Out at IMS 2026? Five Myeloma Experts Weigh In

Telehealth May Offer a Path to More Equitable Myeloma Transplant Access